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Fifteen-month circulatory support for sustained ventricular fibrillation by
left ventricular assist device
Motonobu Nishimura, MD, Masanori Ogiwara, MD, Masayuki Ishikawa, MD, Syogo Yatsu, MD, Ayumu Masuoka, MD,
Nobuyuki Okamura, MD, Kazuhito Imanaka, MD, Masaaki Kato, MD, Haruhiko Asano, MD, and Shunei Kyo, MD,
Saitama, Japan
Patients with end-stage heart failure who receive supportfrom a left ventricular assist system (LVAS) have beenshown to tolerate malignant ventricular arrhythmia fairlywell.1,2 The duration of malignant arrhythmia in the
previous reports was at most a little more than 10 days. This report
describes a patient who has been in sustained ventricular fibrilla-
tion (VF) for more than 1 year and has been supported by an
LVAS without showing any symptoms.
Clinical Summary
A 24-year-old woman, who demonstrated dilated cardiomyopathy,
was first referred to us for heart failure and ventricular arrhythmia
5 years ago. At that time, she received the maximum medication
and did well. She remained well until the age of 23 years, when she
returned with profound heart failure and ventricular tachyarrhyth-
mia resistant to medical therapy. Catecholamine was administered,
and workup for cardiac transplantation was started. She experi-
enced VF and was resuscitated using the percutaneous extracor-
poreal membrane oxygenator system (Emersave, Terumo, Tokyo,
Japan). She was immediately brought to the operating room, where
she underwent emergency placement of the Toyobo-NCVC LVAS
(Toyobo, Osaka, Japan) with left ventricular drainage. Her post-
operative course was essentially uneventful, but her ventricular
arrhythmia continued despite aggressive antiarrhythmia medica-
tion. Three months after placement of the LVAS, she experienced
VF again, which was resistant to external cardioversion (Figures
1A and 1B). Although her heart had been fibrillated, her LVAS
flow was almost unchanged (3-4 L/min), and she showed no
symptoms. Despite all the attempts to restore her original rhythm,
she remained in VF. After several days, we stopped the attempts
because she had been well with no symptoms, and further attempts
may have caused embolism as the result of intracardiac thrombus.
Since then, her heart has been in sustained VF for 15 months, but
she has been ambulated, like other patients supported by an LVAS,
while awaiting heart transplantation (Figure 2). Although her right
ventricle is not working, she has not demonstrated peripheral
edema, pleural effusion, or ascites. Her pulmonary vascular resis-
tance before LVAS placement was 2.44 Wood units. Her central
venous pressure 3 months after demonstrating VF was approxi-
mately 10 mm Hg. Cardiac catheterization was not performed after
sustained VF because of possible thrombus in her fibrillated heart.
Discussion
Sustained VF is not a lethal arrhythmia for patients supported by
an LVAS. In a report by Oz and associates,1 an LVAS was
successful in supporting 9 patients who continued to experience
malignant ventricular arrhythmia during device support. The ar-
rhythmias lasted from 10 minutes to 12 days. The patients reported
weakness, but none reported syncope. Fasseas and coworkers3
reported the successful use of an LVAS for the management of
refractory ventricular arrhythmia. Nonetheless, early electrical car-
dioversion is indicated in patients demonstrating sustained VF
with LVAS support because usually there is more than a 1 L/min
decrease in device flow at the onset of VF.1
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This is a rare case of a patient who has demonstrated sustained
VF for more than 1 year and has been successfully supported by an
LVAS. She is ambulatory without showing any symptoms, which
is one of the reasons that we stopped attempting cardioversion.
Otherwise, placement of a right ventricular assist device would be
indicated in this setting as reported by Farrar and colleagues.4
There are 2 reasons why she remains in good shape in sustained
VF while supported by an LVAS: (1) She has normal pulmonary
vascular resistance (2.44 Wood units), which allows her a kind of
Fontan circulation with an LVAS. (2) Her body size (body surface
area of 1.42 m2) is small enough to maintain whole circulation
with 1 Toyobo-NCVC LVAS, a pneumatically driven paracorpo-
Figure 1A. Electrocardiogram of limb leads shows sustained VF 1 year after the onset of VF.
Figure 1B. Chest x-ray film 1 year after the onset of VF shows no
pulmonary congestion but marked dilation of the right side of the
heart.
Figure 2. The patient with paracorporeal LVAS is walking in the
hallway while her heart is in VF.
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real ventricular assist device developed in Japan. However, al-
though she is able to walk around the hallway, her exercise
capacity is very limited. Her latest data of peak oxygen consump-
tion during exercise was 6.9 mL · min1 · kg1. Additional
placement of a right ventricular assist device may improve her
exercise capacity, but the risk of device-related complication
would increase with biventricular assist. In Japan, the mean wait-
ing period for a status-1 heart transplant candidate is more than 1
year. To minimize possible complication, univentricular assist is
better for prolonged support lasting more than 1 year.
Experimentally, Takano and coworkers5 have shown the
possibility of prolonged circulatory maintenance with an LVAS
by studying goats in VF. To our knowledge, this is the first
clinical case demonstrating that long-term circulatory support
of a non-heart-beating patient is possible with left ventricular
support only, when pulmonary vascular resistance is in the
normal range.
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Combination of the HEARTSTRING proximal seal
system with a blower mister: A possible source of
gas emboli
Georg Nollert, MD, Martin Oberhoffer, MD, Bruno Reichart, MD, and Calin Vicol, MD,
Munich, Germany
Using a side clamp for the performance of proximalanastomoses in coronary artery bypass surgery mayinjure the ascending aorta and cause intimal tears,with subsequent dissection or debridement of athero-
sclerotic material and stroke. Several devices were developed to
perform proximal bypass anastomoses without the necessity of
side clamping, the latest being the HEARTSTRING proximal seal
system (Guidant Corp, Santa Clara, Calif). The system comprises
the proximal seal, a delivery device, and an aortic punch. The
proximal seal is delivered into the aorta via a punch hole site and
provides a sealed region to facilitate the proximal anastomosis.1
The proximal seal covers the punch hole from inside the aorta,
because the blood pressure pushes and a tension spring mechanism
pulls the seal against the aortic wall.
Patient
The first use of the HEART-
STRING device in our clinic
was scheduled in an 83-year-
old woman who presented
with unstable angina. Three
bypasses were implanted including the left internal thoracic artery
connected to the left anterior descending and 2 saphenous vein
grafts for the first diagonal branch and the distal right coronary
artery. The proximal anastomoses were performed with the aid of
the HEARTSTRING device after removal of the crossclamp with-
out using a side clamp. Because of bleeding during the perfor-
mance of the proximal anastomoses, the operative field was
cleared with a blower mister (Medtronic Inc, Minneapolis, Minn)
as recommended by the manufacturer.1 Mean arterial pressure was
above 70 mm Hg. Postoperatively the patient was hemodynami-
cally stable without inotropic support. As the patient did not wake
up a cerebral computed tomography (CT) scan was performed
immediately followed by a second CT of the brain, thorax, and
abdomen 11 hours later. It revealed a new hypodense right frontal
area (2  2 cm large) in the region of the anterior cerebral artery
(see Figure 1) and multiple spleen infarctions.
Animal Experiment
A German land race pig (35 kg) was anesthetized, intubated, and
ventilated. For arterial blood pressure monitoring as well as blood
gas sampling, the right carotid artery was cannulated. The chest
From the Department of Cardiac Surgery, University of Munich, Munich,
Germany.
Received for publication March 11, 2003; accepted for publication April 8,
2003.
Address for reprints: Dr Georg Nollert, Department of Cardiac Surgery,
Klinikum Grosshadern, Marchioninistr 15, 81366, Munich, Germany (E-
mail: gnollert@hch.med.uni-muenchen.de).
J Thorac Cardiovasc Surg 2003;126:1192-4
Copyright © 2003 by The American Association for Thoracic Surgery
0022-5223/2003 $30.00  0
doi:10.1016/S0022-5223(03)00800-6
Dr Nollert
Brief Communications
1192 The Journal of Thoracic and Cardiovascular Surgery ● October 2003
